In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 181 to 190 of 387

TitleTypeExpected publication date
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidanceTBC
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Technology appraisal guidance
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Technology appraisal guidance
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidanceTBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All